Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016149575 - SYNERGISTIC REGULATED CELL DEATH INDUCTION WITH HSP90 INHIBITORS AND NANOSECOND PULSED ELECTRIC FIELDS

Publication Number WO/2016/149575
Publication Date 22.09.2016
International Application No. PCT/US2016/023043
International Filing Date 18.03.2016
IPC
A61N 1/05 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1Electrotherapy; Circuits therefor
02Details
04Electrodes
05for implantation or insertion into the body, e.g. heart electrode
A61N 1/36 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1Electrotherapy; Circuits therefor
18Applying electric currents by contact electrodes
32alternating or intermittent currents
36for stimulation, e.g. heart pace-makers
CPC
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61N 1/0412
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1Electrotherapy; Circuits therefor
02Details
04Electrodes
0404for external use
0408Use-related aspects
0412Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
A61N 1/327
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1Electrotherapy; Circuits therefor
18Applying electric currents by contact electrodes
32alternating or intermittent currents
327for enhancing the absorption properties of tissue, e.g. by electroporation
A61N 1/36002
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1Electrotherapy; Circuits therefor
18Applying electric currents by contact electrodes
32alternating or intermittent currents
36for stimulation
36002Cancer treatment, e.g. tumour
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • OLD DOMINION UNIVERSITY [US]/[US]
Inventors
  • BEEBE, Stephen, J.
  • CATRAVAS, John, D.
Agents
  • NGUYEN, Tram, Anh
Priority Data
62/135,46619.03.2015US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SYNERGISTIC REGULATED CELL DEATH INDUCTION WITH HSP90 INHIBITORS AND NANOSECOND PULSED ELECTRIC FIELDS
(FR) INDUCTION SYNERGIQUE DE MORT CELLULAIRE RÉGULÉE À L’AIDE D’INHIBITEURS DE HSP90 ET DE CHAMPS ÉLECTRIQUES À IMPULSIONS NANOSECONDES
Abstract
(EN)
Methods for treating tumors employing HSp90 inhibitors in combination with nanosecond pulsed electric fields (nsPEFs) are disclosed. The methods are directed to induce regulated cell death (RCD) in tumor cells and tissues. Further, Hsp90 inhibitors in combination with nsPEF are used at low non-toxic concentrations, thereby reducing the side-effects associated with these drugs. Additionally, nsPEFs are employed at lower electric fields and/or with fewer number of pulses than when nsPEFs are employed alone. Further, the mechanisms by which nsPEFs and Hsp90 inhibitors act upon cancer cells are different, thereby combining these treatments results in a synergistic effect.
(FR)
L'invention concerne des procédés pour le traitement de tumeurs mettant en œuvre des inhibiteurs de HSp90 associés à des champs électriques à impulsions nanosecondes (nsPEF). L'invention concerne des procédés visant à induire la mort cellulaire régulée (RCD) dans des cellules tumorales et des tissus. En outre, des inhibiteurs de Hsp90 associés à des nsPEF sont utilisés à faibles concentrations non-toxiques, ce qui permet de réduire les effets secondaires associés auxdits médicaments. En outre, les nsPEF sont utilisés sous forme de champs électriques inférieurs et/ou en comptant un nombre d'impulsions moins important que lorsque les nsPEF sont utilisés seuls. En outre, les mécanismes par lesquels les nsPEF et les inhibiteurs de Hsp90 agissent sur les cellules cancéreuses sont différents, ainsi la combinaison desdits traitements permet l’obtention d’un effet synergique.
Also published as
Latest bibliographic data on file with the International Bureau